Episode 91
91: Assessing the Landscape of Sleep Disorder Care
June 16, 202319m 14s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Ann Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, who sat down with NeurologyLive at the annual SLEEP meeting to discuss the landscape of challenges narcolepsy-related challenges that patients face, the influence of gut health on sleep apnea, how nighttime disruptions can affect treatment decisions, emerging concepts of care, and much more.
Looking for more Sleep Disorder discussion? Check out the NeurologyLive® sleep disorder clinical focus page.
Episode Breakdown:
In this episode, we spoke with Ann Marie Morse, DO, FAAN, a pediatric neurologist and sleep medicine specialist at Geisinger Medical Center, who sat down with NeurologyLive at the annual SLEEP meeting to discuss the landscape of challenges narcolepsy-related challenges that patients face, the influence of gut health on sleep apnea, how nighttime disruptions can affect treatment decisions, emerging concepts of care, and much more.
Looking for more Sleep Disorder discussion? Check out the NeurologyLive® sleep disorder clinical focus page.
Episode Breakdown:
- 1:15 – Factors at play in obstructive sleep apnea
- 3:40 – Literature on the gut microbiome's role in sleep
- 5:55 – Lingering needs in narcolepsy treatment
- 8:30 – Neurology News Minute
- 12:40 – The effect of disrupted nighttime sleep
- 15:45 – Emerging concepts in sleep medicine
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease
- FibroGen's Duchenne Muscular Dystrophy Antibody Pamrevlumab Falls Short in Phase 3
- Phase 2/3 Study of Blarcamesine in Pediatrics With Rett Syndrome Completes Enrollment
- FDA Places Hold on Phase 1 Study of Exon Skipping Therapy PGN-EDODM1 in Myotonic Muscular Dystrophy
- FDA Panel Votes in Favor of Eisai’s Lecanemab for Early Alzheimer Disease
- Post-Marketing Study of Andexanet Alfa Stopped Early After Achieving Prespecified Efficacy
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.